Boster Immunoleader

antibody

Anti-SKP2 Antibody

PA1102

100 ug/vial

200 USD

polyclonal

rabbit

human, mouse, rat

western blot, immunohistochemistry - paraffin section

Anti-SKP2 Antibody

PA1102

Polyclonal

Rabbit IgG polyclonal antibody for S-phase kinase-associated protein 2(SKP2) detection. Tested with WB, IHC-P in Human;Mouse;Rat.

200 USD

Rabbit IgG

100 ug/vial

Lyophilized

No cross reactivity with other proteins.

Reacts with: human, rat Predicted to work with: mouse

WB,IHC-P

Concentration: 0.1-0.5μg/ml; Tested Species: Human, Rat; Predicted Species: Mouse

Concentration: 0.5-1μg/ml; Tested Species: Human, Rat; Predicted Species: Mouse

Tested Species: In-house tested species with positive results. Predicted Species: Species predicted to be fit for the product based on sequence similarities. By Heat: Boiling the paraffin sections in 10mM citrate buffer, pH6.0, for 20mins is required for the staining of formalin/paraffin sections. Other applications have not been tested. Optimal dilutions should be determined by end users.

A synthetic peptide corresponding to a sequence at the N-terminus of human SKP2(2-20aa HRKHLQEIPDLSSNVATSF), different from the related rat and mouse sequences by three amino acids.

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3.

Immunogen affinity purified.

Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

At -20˚C for one year. After reconstitution, at 4˚C for one month. It can also be aliquotted and stored frozen at -20˚C for a longer time. Avoid repeated freezing and thawing.

Boster provides a series of assays reacted with primary antibodies. Antibody can be supported by chemiluminescence kit EK1002 in WB, supported by SA1022 in IHC(P).

The F box protein Skp2(S-phase kinase-associated protein 2) is oncogenic, and its frequent amplification and overexpression correlate with the grade of malignancy of certain tumors. Skp2 controls p300-p53 signaling pathways in cancer cells, making it a potential molecular target for cancer therapy. This gene positively regulates the G(1)-S transition by controlling the stability of several G(1) regulators, such as the cell cycle inhibitor p27. This study provides evidence of a role for an F-box protein in oncogenesis and establishes SKP2 as a protooncogene causally involved in the pathogenesis of lymphomas.

1. Kitagawa, M.; Lee, S. H.; McCormick, F. : Skp2 suppresses p53-dependent apoptosis by inhibiting p300. Molec. Cell 29: 217-231, 2008. 2. Latres, E.; Chiarle, R.; Schulman, B. A.; Pavletich, N. P.; Pellicer, A.; Inghirami, G.; Pagano, M. : Role of the F-box protein Skp2 in lymphomagenesis. Proc. Nat. Acad. Sci. 98: 2515-2520, 2001.

SKP2

S-phase kinase-associated protein 2

S-phase kinase-associated protein 2, E3 ubiquitin protein ligase

CDK2/Cyclin A associated protein p45 antibody Cyclin A/CDK2 associated protein p45 antibody Cyclin-A/CDK2-associated protein p45 antibody F box protein Skp2 antibody F box/LRR repeat protein 1 antibody F-box protein Skp2 antibody F-box/LRR-repeat protein 1 antibody FBL 1 antibody FBL1 antibody FBXL 1 antibody FBXL1 antibody FLB 1 antibody FLB1 antibody MGC1366 antibody p45 antibody p45skp2 antibody S phase kinase associated protein 2 antibody S-phase kinase-associated protein 2 antibody SKP 2 antibody Skp2 antibody SKP2_HUMAN antibody

Q13309